Last update 12 Dec 2024

JSKN-003

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
JSKN 003, JSKN-003, JSKN003
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC26H24FN3O6
InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N
CAS Registry1599440-33-1

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2-Low Breast CarcinomaPhase 3
CN
14 Nov 2023
Advanced Malignant Solid NeoplasmPhase 2
CN
02 Mar 2023
Metastatic Solid TumorPhase 1
AU
02 Sep 2022
HER2 Positive Solid TumorsIND Approval
CN
13 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
50
fcvonpvfxc(qknlamphul) = sdoijoydif xxiqqycyhr (oaheoxsicl )
Positive
17 Sep 2024
Phase 1/2
29
jmqmgjekly(xwgdxfhrjj) = gahnhtfuox otxzdeuisl (rqblxjnwlu )
Positive
17 Sep 2024
Phase 1/2
27
mudnnuzmcu(oyyyfixqeu) = azbsurmmyu npjhpauork (swjkxcuzzy )
Positive
14 Sep 2024
JSKN003
(HER2 IHC 1+、2+ 和 3+)
fpzdyaewde(dzytqhlhfx) = ozhranpmer jymnjfsvue (amvpbrqmbw )
Phase 1/2
24
vobqwsgwed(bvflczrsbd) = noqftfkvpx ouxlmiqdja (kqwqkkxqkv )
Positive
14 Sep 2024
Phase 1/2
Solid tumor
HER2 Expression
46
fgleeiooit(ehbscvbygf) = yglwdquwur ozytphnjtu (puztjoolzv, 35.8 - 66.3)
Positive
04 Jun 2024
Phase 1/2
Advanced Malignant Solid Neoplasm
HER2-expressing | HER2-mutant
46
vmaifxgcql(nccqmgqnhg) = No pts experienced DLT or interstitial lung disease, and no TRAE led to death or discontinuation cvcqmffiyt (gdfgwxzmdk )
Positive
24 May 2024
Phase 1
Solid tumor
ERBB2 Mutation (Activating) | HER2 Expression
32
lydtjfobng(opmtbfliom) = not been reached. jsqmvhaukn (bbpfujbpin )
Positive
05 Apr 2024
Phase 1
32
zstbiwmsfg(wotzoakhgl) = ttefyhptbr mefgmpekys (imsvtaghdd )
Positive
16 Nov 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free